Design of a Novel Gene Therapy Construct to Achieve Sustained Brain-Derived Neurotrophic Factor Signaling in Neurons
Open Access
- 1 July 2018
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 29 (7) , 828-841
Abstract
Brain-derived neurotrophic factor (BDNF) acting through the tropomyosin-related receptor-B (TrkB) is an important signaling system for the maintenance and survival of neurons. Gene therapy using either recombinant adeno-associated virus (AAV) or lentiviral vectors can provide sustained delivery of BDNF to tissues where reduced BDNF signaling is hypothesized to contribute to disease pathophysiology. However, elevation in BDNF at target sites has been shown to lead to a downregulation of TrkB receptors, thereby reducing the effect of chronic BDNF delivery over time. A novel gene sequence has been designed coding both the ligand (BDNF) and the TrkB receptor in a single transgene separated by a short viral-2A sequence. The single transgene is efficiently processed intracellularly in vitro and in vivo to yield the two mature proteins, which are then independently transported to their final cellular locations: TrkB receptors to the cell surface, and BDNF contained within secretory vesicles. To accommodate the coding sequences of both BDNF and TrkB receptors within the narrow confines of the AAV vectors (4.7 kb pairs), the coding region for the pro-domain of BDNF was removed and the signal peptide sequence modified to improve production, intracellular transport, and secretion of mature BDNF (mBDNF). Intracellular processing and efficacy was shown in HEK293 cells and SH-SY5Y neuroblastoma cells using plasmid DNA and after incorporating the TrkB-2A-mBDNF into an AAV2 vector. Increased BDNF/TrkB-mediated intracellular signaling pathways were observed after AAV2 vector transfection while increased TrkB phosphorylation could be detected in combination with neuroprotection from hydrogen peroxide–induced oxidative stress. Correct processing was also shown in vivo in mouse retinal ganglion cells after AAV2 vector administration to the eye. This novel construct is currently being investigated for its efficacy in animal models to determine its potential to progress to human clinical studies in the future.Keywords
This publication has 51 references indexed in Scilit:
- BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neuronsJournal of Cell Biology, 2012
- Identification of a low–molecular weight TrkB antagonist with anxiolytic and antidepressant activity in miceJournal of Clinical Investigation, 2011
- Chronic and Acute Models of Retinal Neurodegeneration TrkA Activity Are Neuroprotective whereas p75NTR Activity Is Neurotoxic through a Paracrine MechanismJournal of Biological Chemistry, 2010
- Postsynaptic BDNF‐TrkB signaling in synapse maturation, plasticity, and diseaseDevelopmental Neurobiology, 2010
- Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's diseaseNature Medicine, 2009
- Dissecting the human BDNF locus: Bidirectional transcription, complex splicing, and multiple promotersGenomics, 2007
- TrkB/BDNF signaling regulates photoreceptor progenitor cell fate decisionsDevelopmental Biology, 2006
- Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neuronsGene Therapy, 2001
- Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC 1 1Edited by I. A. WilsonJournal of Molecular Biology, 1999
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991